In the cohort D of the SOHO-01 phase I/II trial, which included 44 patients with HER2 MUT (Ex20) NSCLC who were pretreated but naïve for anti-HER2 therapies, BAY2927088 achieved an ORR of 72.1%, a DCR 96%, and a mPFS of 7.5 months. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.